louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00218413: Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals
Official title: A Phase 2 Study to Assess Safety and Immunogenicity of Five Doses of 3'-Aminomethylnicotine-P. Aeruginosa r-Exoprotein A Conjugate Vaccine (NicVAX) Administered to Smokers
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Smoking Cessation
Tobacco Use Cessation
Keywords: Vaccine
Immunogenicity
Randomized Controlled Trial
Addiction
Lead sponsor: National Institute on Drug Abuse (NIDA)
Sponsor class: NIH
Collaborators: name: National Institute on Drug Abuse (NIDA)
First posted: 2005-09-22
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Nicotine is highly addictive and many individuals are unable to quit smoking even with treatment. The purpose of this study is to determine the effectiveness of various doses of NicVAX in treating nicotine dependent individuals.

Detailed description: Tobacco use is the single leading preventable cause of death in the United States. Nicotine is an alkaloid that is derived from the tobacco plant responsible for the psychoactive and addictive effects of smoking. Immunotherapy may be useful in preventing and treating nicotine dependent individuals. NicVAX is a nicotine vaccine, a type of immunotherapy that may be effective in smoking cessation and preventing relapse to nicotine. The purpose of this study is to evaluate the safety and efficacy of various dosing levels and dosing frequencies of NicVAX in treating nicotine dependent individuals.

Eligibility criteria: Inclusion Criteria:

* Current smoker
* Good general health, including mental health
* Alveolar carbon monoxide level greater than or equal to 10 ppm

Exclusion Criteria:

* Prior exposure to NicVAX
* Known allergy to any of the components of NicVAX
* Use of any smoking cessation aide
* Pregnant or breastfeeding

Primary outcomes:
measure: Anti-nicotine Antibody concentrations
timeFrame: 19 time points from Day 0 to 365
Secondary outcomes:
measure: Smoking cessation
timeFrame: periods of 2 weeks, 4 weeks, or 12 weeks duration
measure: Fagerstrom Test for Nicotine Dependence
timeFrame: 7 time points from Day 0 to 365
measure: Safety: vaccine reactogenicity
timeFrame: 7 days after each dose
measure: Safety: adverse events
timeFrame: Day 0-365
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: University of Maastricht
Study officials:
affiliation: Nabi Biopharmaceuticals
name: Gary Horwith
role: PRINCIPAL_INVESTIGATOR
affiliation: Nabi Biopharmaceuticals
name: Arjen De Vos, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04762719: PET Imaging to Delineate Macrophage Activation in Diabetic Gastroparesis
Official title: Dynamic Positron Emission Tomography Imaging With 11C-ER176 to Delineate Macrophage Activation in Diabetic Gastroparesis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Diabetes
Gastroparesis With Diabetes Mellitus
Keywords: macrophages, immune cells, gastric emptying, gastroparesis, imaging
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2021-02-21
Enrollment: 12
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Intervention model description: Three groups of patients (diabetic; diabetic gastroparesis; healthy volunteers) will undergo PET-CT. The diabetic gastroparesis group will also undergo gastric muscle biopsy of the involved and uninvolved area to validate immune changes visualized on imaging.
Primary purpose: DIAGNOSTIC

Brief summary: Macrophage-driven immune dysregulation has been shown to be involved in pathophysiology of diabetic gastroparesis. Currently, there are no non-invasive ways to study macrophage activation in humans. The researchers are trying to determine the utility of 11C-ER176 based PET-CT scanning to determine pro-inflammatory macrophage activation in gastric wall of patients with diabetic gastroparesis.


Eligibility criteria: Inclusion Criteria:

* Age: 18 to 70 years of age.
* Ability to provide informed consent.
* Type I or II diabetes mellitus.
* Gastroparesis defined by gastric retention of Tc-99m \> 60 % at 2 hrs and/or \> 10% at 4 hours on scintigraphy.
* Average Gastroparesis Cardinal Symptom Index (GCSI) ≥ 3 indicating moderate-severe symptoms.

Exclusion Criteria:

* Women who are pregnant or cannot stop breast feeding for 24 hours.
* Using anti-coagulants, anti-inflammatory medications (NSAIDs, corticosteroids, etc.) or immunosuppressive therapies within the 4 weeks prior.
* Opioid use within the last 4 weeks of gastric emptying scintigraphy.
* Prior gastric surgery.
* History of IBD, celiac disease, eosinophilic gastroenteritis, microscopic colitis.

Healthy Subjects Exclusion criteria

* no clinical history of diabetes or any GI symptoms
* no inflammatory disorders of the GI tract
* no use of anti-inflammatory or immunosuppressive therapies

Primary outcomes:
measure: Uptake of 11C-ER 176 in the Stomach Muscle
timeFrame: baseline
Secondary outcomes:
measure: Percentage of Immune Cells With CD45 Expression
timeFrame: baseline
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic in Rochester
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Madhusudan Grover, MBBS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02538419: Group-based Peer Support Versus Individual Education for Patients Undergoing CPAP Treatment
Official title: Group-based Peer Support Versus Individual Education for Patients Undergoing CPAP Treatment
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Sleep Apnea, Obstructive
Lead sponsor: Brigham and Women's Hospital
Sponsor class: OTHER
First posted: 2015-09-02
Enrollment: 40
Sex: ALL
Minimum age (years): 21
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The investigators will compare two alternatives designed to maximize adherence to continuous positive airway pressure (CPAP) therapy for obstructive sleep apnea (OSA) - peer-support administered in groups, versus individual education.

Detailed description: The study is a 6-week, open-label, parallel-arm, randomized controlled trial comparing peer support and individual education (the latter of which was designed to mimic usual care). Participants in the peer-support (intervention) arm will be encouraged to attend two peer-support sessions, with one session occurring immediately prior to beginning CPAP and the other occurring two weeks later. Participants in the individual education (comparator) arm will begin CPAP without attendance at any peer-support sessions.

Eligibility criteria: Inclusion Criteria:

* Diagnosed with obstructive sleep apnea (no cut-off for severity)
* Prescribed continuous positive airway pressure

Exclusion Criteria:

* Not fluent in English
* Prior CPAP use at home
* Current use of any non-CPAP treatment for obstructive sleep apnea
* A co-morbid sleep disorder
* Use of supplemental oxygen
* A clinical need for urgent CPAP therapy

Primary outcomes:
measure: Adherence
timeFrame: 6 weeks
Secondary outcomes:
measure: Percentage of Participants With Adherence >=4 Hours/Night on Average
timeFrame: 6 weeks
measure: FOSQ
timeFrame: 6 weeks
measure: SEMSA - Perceived Risk
timeFrame: 6 weeks
measure: SEMSA - Outcome Expectations
timeFrame: 6 weeks
measure: SEMSA - Self Efficacy
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Boston
country: United States
facility: Brigham and Women's Hospital
state: Massachusetts
Study officials:
affiliation: Brigham and Women's Hospital
name: Susan Redline, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03837119: Maternal and Perinatal Pregnancy Outcome in Women With Heterozygous Hemoglobinopathies
Official title: Maternal and Perinatal Pregnancy Outcome in Women With Heterozygous Hemoglobinopathies
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Heterozygous Haemoglobinopathy
Keywords: pregnancy
gestational diabetes
cholestasis in pregnancy
urinary tract infection in pregnancy
Lead sponsor: University Hospital, Basel, Switzerland
Sponsor class: OTHER
First posted: 2019-02-11
Enrollment: 540
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: pregnant women being treated at Universitätsspital Basel/ Frauenklinik (from 2015 until 2017) and at Universitätsspital Zürich (from 2004-2006)

Brief summary: This retrospective study aims to investigate pregnancy outcome in women with heterozygous hemoglobinopathies (regarding gestational diabetes, cholestasis and urinary tract infections) and to analyze if there are aggravated maternal and/or perinatal risks.


Eligibility criteria: Inclusion Criteria:

* pregnant women with or without heterozygous hemoglobinopathy

Exclusion Criteria:

* refusal of study participation

Primary outcomes:
measure: gestational diabetes
timeFrame: in the course of pregnancy until delivery
measure: cholestasis in pregnancy
timeFrame: in the course of pregnancy until delivery
measure: urinary tract infection
timeFrame: in the course of pregnancy until delivery
Secondary outcomes:
Other outcomes:
Locations:
city: Basel
country: Switzerland
facility: Frauenklinik University Hospital Basel
city: Zürich
country: Switzerland
facility: Frauenklinik University Hospital Zürich
Study officials:
affiliation: Frauenklinik Universitätsspital Basel
name: Irene Hoesli, Prof. Dr. MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kasparek J, Burkhardt T, Hoesli I, Amstad Bencaiova G. Pregnancy outcomes in women with a hemoglobinopathy trait: a multicenter, retrospective study. Arch Gynecol Obstet. 2021 Nov;304(5):1197-1203. doi: 10.1007/s00404-021-06058-y. Epub 2021 Apr 11.
Clinical trial NCT02708719: Development of a MID for the 1-minute Sit-to-stand Test
Official title: Development of a Minimal Important Difference for the 1-minute Sit-to-stand Test
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COPD
Keywords: COPD
MID
1-minute sit-to-stand-test
Lead sponsor: Schön Klinik Berchtesgadener Land
Sponsor class: OTHER
Collaborators: name: AstraZeneca
First posted: 2016-03-15
Enrollment: 105
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine the minimal important difference (MID) for the 1-minute-sit-to-stand-test (STST) with an anchor-based method.

Detailed description: In this study we develop the minimal important difference for the 1-minute sit-to-stand-test (STST) with an anchor-based method.

First step of this study is to find out the differences in the number of repetitions during 1-minute STST, 6-minute walk distance and health-related quality of life from pre to post inpatient pulmonary Rehabilitation program (3 weeks Duration) in the Schoen-Klinik Berchtesgadener Land.

In Addition, Balance tests on the Leonardo-Mechanograph will be performed and the Hospital Anxiety and Depression Scale (HADS) and Chronic Respiratory Questionnaire (CRQ) will be assessed.

For the second step we will use an anchor-based approach to estimate the MID of the STST. 6MWD and CRQ are used as anchors for which the MID has been established before.

Eligibility criteria: Inclusion Criteria:

* Patients with COPD (GOLD-Stage II to IV)
* Ability to stand-up and walk
* written informed consent

Exclusion Criteria:

* orthopaedic or other comorbidities that prevent patients from performing the STST, 6MWT or exercise Training
* acute exacerbation
* heart failure, acute coronary syndrome

Primary outcomes:
measure: MID of the 1-minute-STST
timeFrame: 21 days
Secondary outcomes:
measure: 6-minute-walk distance
timeFrame: 21 days
measure: CRQ Score
timeFrame: 21 days
Other outcomes:
Locations:
city: Schönau am Königssee
country: Germany
facility: Berchtesgardener Land
state: Bayern
Study officials:
affiliation: Schoen Klinik BGL
name: Klaus Kenn, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06251219: Active Case Finding of Clinical Hand Foot Mouth Disease in Children Aged 6 Months Old to 18 Years Old in Indonesia
Official title: Active Case Finding of Clinical Hand Foot Mouth Disease in Children Aged 6 Months Old to 18 Years Old in Indonesia
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Hand, Foot and Mouth Disease
Lead sponsor: Sinovac Biotech Co., Ltd
Sponsor class: INDUSTRY
First posted: 2024-02-09
Enrollment: 100
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with clinically diagnosed cases of HFMD will be enrolled during the epidemic season within one year or earlies.

Brief summary: An observational study of active case surveillance to identify the pathogens of clinically diagnosed HFMD cases aged 6 months to 18 years old recruited from puskesmas and hospitals in Indonesia.

Detailed description: Every time suspected case of HFMD presented to the hospital, the pediatrician will inform the patient to enroll in the study. After the subject signs the informed consent, the pediatrician will give the subject designated number to enroll to the study. After gathering general information, medical history, and physical examination, the eligibility of participants will be assessed. The subject that fulfills the eligibility criteria will be enrolled in the study. All participants will collect stool sample or rectal swab to be tested with PCR test for EV71, CA (planned serotypes 16/10/6). If the result is positive, the sample will be further tested with genotype sequencing of EV71 and CoxA. For subject with respiratory symptom, skin lesion or encephalitis, extra PCR testing will be collected for PCR testing. Blood sample will also be collected from all subjects. Only 20 subjects with positive PCR result that will be tested for SVNT and PRNT. Two weeks following participant recruitment, study staff will contact the participant by phone and document the outcome of the disease as well the subject's condition.

Eligibility criteria: Inclusion Criteria:

* Clinically diagnosed HFMD children of either sex, aged 6 months - 18 years old in the study sites
* The participant's parent/ legally accepted representative (LAR) could understand and sign a documented informed consent voluntarily before the study procedures.

Exclusion Criteria:

* NA.

Primary outcomes:
measure: To identify the pathogens (EV71, CA16, CA10, and CA6) in clinically diagnosed HFMD childrenCA16, CA10, or CA6
timeFrame: 12 months
Secondary outcomes:
measure: To describe the clinical manifestation (symptom and severity etc.) of clinically diagnosed HFMD children
timeFrame: 12 months
measure: To describe the genotypes of HFMD cases caused by EV71, CA16, CA10, and CA6
timeFrame: 12 months
measure: To investigate role of previous infection of enterovirus EV71, coxsackie virus
timeFrame: 12 months
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00438919: A Multi-center Post-Market Surveillance Registry
Official title: The e-SELECT Registry a MULTICENTER POST-MARKET SURVEILLANCE
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Coronary Artery Disease
Lead sponsor: Cordis Corporation
Sponsor class: INDUSTRY
First posted: 2007-02-22
Enrollment: 15000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This multicenter, prospective, observational registry will evaluate the safety and performance of the CYPHER SELECT™ Sirolimus-eluting Coronary Stent, and of all future generation of commercially approved Cordis Sirolimus-eluting Stents (SES), in routine clinical practice. Its objective is to measure the incidence and identify the predictors of acute, sub-acute and late stent thrombosis and Major Adverse Cardiac Events (MACE). Additional analyses will be performed in patient sub-populations, such as diabetes, in-stent restenosis (ISR), acute myocardial infarction (AMI) and multivessel coronary disease.

Detailed description: The data will be collected in consecutive subjects treated with commercially available product and following standard clinical practice. This registry will be limited to subjects who have received only the CYPHER SELECT™ Sirolimus-eluting Coronary Stent during the index procedure. While no inclusion or exclusion criteria have been specified, uniform, complete and accurate data will be collected peri-procedurally, during the index hospitalization, and during follow-up. All subjects should be treated according to the Instruction For Use (IFU) including conduct of the stenting procedure, application of antiplatelet medication and any other medical therapy should be provided according to local usual practice. Data collection (Electronic Data Capture), data management, statistical analyses, monitoring and core laboratory evaluations will be assigned to independent organizations.

Eligibility criteria: Inclusion Criteria:

* This registry will be limited to subjects who have received only the CYPHER SELECT™ Sirolimus-eluting Coronary Stent during the index procedure;
* Males and females;

Exclusion Criteria:

* None.

Primary outcomes:
measure: acute, sub-acute and late stent thrombosis; Major Adverse Cardiac Events (MACE)
timeFrame: 1, 6, 12, 24 and 36 months
Secondary outcomes:
Other outcomes:
Locations:
city: Meyrin
country: Switzerland
facility: Clinique La Tour
Study officials:
affiliation: Clinique La Tour
name: Philip Urban, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Urban P, Abizaid A, Banning A, Bartorelli AL, Baux AC, Dzavik V, Ellis S, Gao R, Holmes D, Jeong MH, Legrand V, Neumann FJ, Nyakern M, Spaulding C, Worthley S; e-SELECT Investigators. Stent thrombosis and bleeding complications after implantation of sirolimus-eluting coronary stents in an unselected worldwide population: a report from the e-SELECT (Multi-Center Post-Market Surveillance) registry. J Am Coll Cardiol. 2011 Mar 29;57(13):1445-54. doi: 10.1016/j.jacc.2010.11.028.
Clinical trial NCT01473719: Emerging Adults Who Use Alcohol and Marijuana
Official title: Reducing STIs in Emerging Adults Who Use Alcohol and Marijuana
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Alcohol Use
Marijuana Use
Sexually Transmitted Infections
Keywords: alcohol use
marijuana use
STI
Lead sponsor: Butler Hospital
Sponsor class: OTHER
First posted: 2011-11-17
Enrollment: 566
Sex: ALL
Minimum age (years): 18
Maximum age (years): 25
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to if a brief motivational intervention, compared to health education sessions, reduces alcohol and marijuana use and is related to fewer sexually transmitted infections (STI)in emerging adults who are engaging in alcohol and marijuana use.


Eligibility criteria: Inclusion Criteria:

* Be between the ages of 18 and 25
* Binge drink (5 or more drinks in a 2-hour period for men, 4 or more for women) at least monthly
* Use marijuana at least weekly
* Have been heterosexually active in the past six months
* Are not married
* Have not been living with a sexual or romantic partner for more than 6 months
* Be English speaking
* Reside within 20 miles of Providence, RI and plans to stay in the geographic area for the next 15 months
* Provide contact information for at least two verifiable locator persons

Exclusion Criteria:

* Have DSM-IV diagnosis of drug abuse or dependence (other than nicotine, marijuana)
* Have DSM-IV diagnosis of alcohol dependence

Primary outcomes:
measure: alcohol use
timeFrame: 15 months
measure: marijuana use
timeFrame: 15 months
measure: sexually transmitted infection
timeFrame: 15 months
Secondary outcomes:
Other outcomes:
Locations:
city: Providence
country: United States
facility: Butler Hospital
state: Rhode Island
Study officials:
affiliation: Butler Hospital
name: Michael D Stein, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Caviness CM, Anderson BJ, Stein MD. Impact of Nicotine and Other Stimulants on Sleep in Young Adults. J Addict Med. 2019 May/Jun;13(3):209-214. doi: 10.1097/ADM.0000000000000481.
citation: Caviness CM, Anderson BJ, Stein MD. Energy drinks and alcohol-related risk among young adults. Subst Abus. 2017 Oct-Dec;38(4):376-381. doi: 10.1080/08897077.2017.1343217. Epub 2017 Jun 16.
citation: Moitra E, Christopher PP, Anderson BJ, Stein MD. Coping-motivated marijuana use correlates with DSM-5 cannabis use disorder and psychological distress among emerging adults. Psychol Addict Behav. 2015 Sep;29(3):627-32. doi: 10.1037/adb0000083. Epub 2015 Apr 27.
citation: Caviness CM, Tzilos G, Anderson BJ, Stein MD. Synthetic Cannabinoids: Use and Predictors in a Community Sample of Young Adults. Subst Abus. 2015;36(3):368-73. doi: 10.1080/08897077.2014.959151. Epub 2014 Sep 15.
Clinical trial NCT05185219: The Effect of Valerian on Insomnia in Menopausal Women
Official title: The Effect of Valerian on Insomnia in Menopausal Women: Randomized Placebo-controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Menopausal Women
Insomnia
Keywords: menopause
insomnia
valerian
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2022-01-11
Enrollment: 100
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Menopausal women often complain that it is difficult to fall asleep and easy to wake up at night and early in the morning and it is in the middle of night difficult to fall asleep again. If the above symptoms persist for at least three months and occur at least three times a week, plus the impact on daytime work and rest, and meet the International Classification of Sleep Disorders (ICSD-3) )'S s "Insomnia" diagnostic criteria. According to statistics, 30% to 60% of women face sleep disorders during menopause.

Detailed description: The investigators expect to receive outpatient admissions in the hospital attached to China Medical University. Menopausal women aged 45-60 years old who have been diagnosed with insomnia who meet criteria of International Classification of Sleep Disorders (ICSD-3) will be randomly assigned for clinical trials. Patients will take two Valerian capsules (1000mg/day) per day for four weeks. Pittsburgh Sleep Index (PSQI) will be used to evaluate subjective sleep quality. TCM patterns will be evaluated by three physicians of TCM gynecology independently before and after taking Valeriana. The data will conduct a biological analysis to compare the difference in sleep quality between the trial group and the control group.

Eligibility criteria: Inclusion Criteria:

1. 45〜60 years old, and is menopaused for at least 1 year。
2. meet the criteria of ICSD-3 for insomnia
3. PSQI \> 5

Exclusion Criteria:

1. psychiatry disease
2. Heart, brain, liver diseases
3. Insomnia is caused by diseases.
4. Steroid used within 6 months
5. pregnant or breastfeeding

Primary outcomes:
measure: Sleep quallity
timeFrame: 30 days
Secondary outcomes:
measure: Traditional Chinese medicine (TCM) constitution
timeFrame: 30 days
Other outcomes:
Locations:
city: Taichung
country: Taiwan
facility: China Medical University
Study officials:
References: